Health Care & Life Sciences » Pharmaceuticals | Suven Life Sciences Ltd.

Suven Life Sciences Ltd. | Balance Sheet

Fiscal year is April-March. All values INR Millions.
2014
2015
2016
2017
2018
Cash & Short Term Investments
699
2,798
2,415
3,101
2,996
Total Accounts Receivable
1,273
1,066
907
755
1,075
Inventories
805
819
846
964
1,470
Other Current Assets
43
87
1,109
991
1,124
Total Current Assets
2,820
4,770
5,277
5,812
6,665
Net Property, Plant & Equipment
1,921
2,788
3,134
3,149
3,423
Total Investments and Advances
19
39
18
18
18
Long-Term Note Receivable
-
-
-
2
2
Intangible Assets
-
2
3
12
28
Other Assets
107
133
33
39
42
Total Assets
4,888
7,759
8,902
9,536
10,509
ST Debt & Current Portion LT Debt
528
471
409
449
261
Accounts Payable
409
439
356
379
568
Income Tax Payable
64
-
999
894
1,043
Other Current Liabilities
549
364
342
358
338
Total Current Liabilities
1,551
1,274
2,106
2,081
2,210
Long-Term Debt
377
614
416
259
14
Provision for Risks & Charges
18
23
24
28
37
Deferred Taxes
276
227
50
19
232
Total Liabilities
2,243
2,166
2,935
2,853
2,825
Common Equity (Total)
2,644
5,593
5,953
6,670
7,674
Total Shareholders' Equity
2,644
5,593
5,953
6,670
7,674
Total Equity
2,644
5,593
5,953
6,670
7,674
Liabilities & Shareholders' Equity
4,888
7,759
8,902
9,536
10,509
Non-Equity Reserves
-
-
15
13
10

About Suven Life Sciences

View Profile
Address
6th Floor, SDE Serene Chambers
Hyderabad TS 500034
India
Employees -
Website http://www.suven.com
Updated 09/14/2018
Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. It operates through the following segments: Manufacturing, Services, and Research & Development. The Manufacturing segment consists of bulk drugs and intermediates under contract services products are developed and produced on an exclusive basis.